A Study to Identify Genetic Markers in Non-Cancerous Prostate Tissues, and Compare to Better Identify the Markers Unique to Prostate Cancer


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 16-001919
    Sponsor Protocol Number: 16-001919

About this study

The purpose of this study is to identify DNA methylation (genetic) markers in non-cancerous prostate tissue, and compare with the markers previously found to be in prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria

  • Male
  • Scheduled for a transurethral prostatectomy enucleation
  • No cancer identified in prostate

Exclusion Criteria

  • Has prostate cancer

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Gettman, M.D.

Closed for enrollment

Contact information:

Karen Doering




Mayo Clinic Footer